GTC
BHVN

Ghost Tree Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Ghost Tree Capital’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-175,000
Closed -$9.01M – 55
2019
Q1 		$9.01M Buy
+175,000
New +$7.56M 2.35% 17
2018
Q3 		– Sell
-2,000
Closed -$122K – 67
2018
Q2 		$122K Sell
2,000
-73,100
-97% -$2.32M 0.04% 46
2018
Q1 		$1.94M Buy
+75,100
New +$2.25M 0.39% 46

Other funds holding BHVN

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Ghost Tree Capital's BHVN Position: Q1 2020 in Review

Ghost Tree Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2020, closing a stake of 40,000 shares — an estimated $2.18M sold.

Ghost Tree Capital first reported a position in BHVN in Q4 2017 and held it in 7 quarters. The position peaked at $14.6M in Q3 2019. 175 funds tracked by Wall St. Rank hold BHVN as of Q1 2020.

  • Ghost Tree Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2020 after selling out during the quarter.
  • Ghost Tree Capital sold 40,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2020, an estimated $2.18M.
  • Ghost Tree Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 7 quarters.
  • Ghost Tree Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $14.6M in Q3 2019.
  • 175 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2020.

Based on Ghost Tree Capital's 13F filing for Q1 2020, filed 15 May 2020.